bevacizumab,panitumumab
takeda,amgen,roche
[]
just-presented paradigm analysis from #gi23: hyperselection using #ctdna instead of tumor sidedness may better determine if a patient should receive first-line panitumumab or bevacizumab: #ascodailynews #gicsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.